ReviewNAM journal2025
New frontiers in anti-cancer drug testing: The need for a relevant In vitro testing model.
Review in NAM journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Octreotide-Mediated Co-Solubilization of Paclitaxel and Docetaxel: A Novel Targeted Formulation for Synergistic Anticancer Chemotherapy.Pharmaceutics · 2026Article
- Uncovering the Potential of 3D Spheroids for Modeling the Cellular Crosstalk Within the Tumor Microenvironment in HNSCC.Biotechnology journal · 2026Review
- Current Study of Alpha-Mangostin in Breast Cancer Therapy: Antioxidant Mechanisms and Redox Modulation from In Silico to In Vivo Studies.Antioxidants (Basel, Switzerland) · 2026Review
- Peptide-Based Nanocomplexes Enable Transferrin-Mediated Uptake and p53-Driven Antitumor Activity in 2D and 3D Glioblastoma Models.International journal of molecular sciences · 2026Article
- A pump-free microfluidic device for integrated multi-functional testing of tumor spheroids.APL bioengineering · 2026Article
- Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug development is a complex process involving multiple stages, including discovery, preclinical testing and clinical trials to ensure safety and efficacy. In vitro testing is crucial for early-stage anti-cancer drug toxicity and efficacy evaluation, often utilizing traditional monolayer cell cultures. Traditional cell cultures involve growing cells in a two-dimensional monolayer, providing a controlled environment for initial drug testing. It does not entirely replicate or mimic human in vivo microenvironment conditions, where the cell-to-cell interaction and cell-to-matrix (Extra Cellular Matrix) interaction which are vital in cellular function are limited in the traditional cell culture method and the preclinical animal testing models. Also, there are ethical considerations to be faced while using animal models, and the spheroid model can be a potential in vitro model that can reduce the use of animal testing. Hence, the spheroid models, which offer a three-dimensional structure more accurately mimic the natural tumor environment enhancing the study of drug interactions and cellular responses. This review focuses on the various anti-cancer drugs such as 5-Fluorouracil (5-FU), Tirapazamine (TPZ), Cisplatin, Resveratrol, Irinotecan and Doxorubicin that are tested in traditional monolayer cell culture and Spheroid models for comparing the efficacy and toxicity results in both using various analytical methods which helps us understand each method's advantages and limitations in drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.